Literature DB >> 25403243

Prostate cancer: Clinical implications of therapeutic sequence in mCRPC.

Ulka Vaishampayan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25403243     DOI： 10.1038/nrurol.2014.308

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

2.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

3.  A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Authors:  Arun A Azad; Raya Leibowitz-Amit; Bernhard J Eigl; Renee Lester; J Connor Wells; R Nevin Murray; Christian Kollmannsberger; Daniel Y C Heng; Anthony M Joshua; Kim N Chi
Journal:  Prostate       Date:  2014-08-29       Impact factor: 4.104

4.  Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Authors:  Rosa Nadal; Zhe Zhang; Hibba Rahman; Michael T Schweizer; Samuel R Denmeade; Channing J Paller; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2014-08-31       Impact factor: 4.104

Review 5.  Castration-resistant prostate cancer: latest evidence and therapeutic implications.

Authors:  Daniel L Suzman; Emmanuel S Antonarakis
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

6.  The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.

Authors:  Michael T Schweizer; Xian C Zhou; Hao Wang; Sunakshi Bassi; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  Eur Urol       Date:  2014-01-24       Impact factor: 20.096

7.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

8.  Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Authors:  Ana M Aparicio; Andrea L Harzstark; Paul G Corn; Sijin Wen; John C Araujo; Shi-Ming Tu; Lance C Pagliaro; Jeri Kim; Randall E Millikan; Charles Ryan; Nizar M Tannir; Amado J Zurita; Paul Mathew; Wadih Arap; Patricia Troncoso; Peter F Thall; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2013-05-06       Impact factor: 12.531
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.